I-Mab Appoints Dr. Sean Fu as Permanent CEO to Lead Advancement of Cancer Immunotherapy Programs

Rockville, MD, November 6, 2024 (PRNewswire) -- I-Mab has named Dr. Sean Fu as its CEO to drive forward its cancer immunotherapy programs.  Dr. Fu has over 20 years of experience in the life sciences industry, having worked at ABio-X as Operating Partner, RVAC Medicines as Co-founder and CEO, Luye Pharma Group as Group VP of International R&D, GeneLeap as CEO (a Luye subsidiary), and Merck & Co. for 15 years in various roles across R&D, business development, and finance. He holds a PhD from Ohio State University and an MBA from Wharton.

Read full article here.